Article

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by Omicron

2022-08-17

Abstract excerpt

The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds SARS-CoV-2 case numbers and maintain a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142 based on its potency and breadth against the VOCs Alpha, Beta, Gamma and Delta for preclinical development into a therapeutic. CV38-142 showed <i>in vivo</i> efficacy i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4ff497ca-143f-53b9-b733-7450f485c8ea
DOI: 10.2139/ssrn.4190668

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronDOI 10.2139/ssrn.4190668Read

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsSemantic proximity Read

Atlas of Currently-Available Human MAbs and Escape to Newly-Emerging Omicron BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.Semantic proximity Read

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variantsSemantic proximity Read

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1Semantic proximity Read